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Abstract
Neoadjuvant therapy is a common form of treatment in locally advanced breast cancer (LABC) patients. Besides some guidelines
for grading regression, a standardized general scheme is not yet available. The aim of our study was to compare the prognostic
impact of different regression grading systems, namely the TR/NR, Chevallier, Sataloff, Denkert-Sinn, Miller-Payne, NSABP-
B18, Residual Disease in Breast and Nodes and Residual Cancer Burden (RCB) on disease-free (DFS) and overall survival (OS).
Data of 746 breast cancer patients treated in neoadjuvant setting between 1999 and 2019 have been included. The different
regression grades and follow-up data were collected frommedical charts. Statistical analysis included the Kaplan-Meier method,
log-rank test and multivariate Cox regression. The average patient age was 55 years. The DFS and OS estimates of patients with
complete pathological regression and residual in situ carcinoma have been significantly more favorable than those having partial
regression or no signs of regression (pDFS<0.001, pOS < 0.001). Significant differences were found between DFS estimates of
classes with partial regression and without regression defined by RCB. Concerning DFS estimates, the RCB classification (p =
0.019), while regarding OS data the y-stage (p = 0.011) and the nodal status (ypN; p = 0.045) were significant prognosticators by
multivariate Cox regression. Regression grading systems help the evaluation of regression in LABC patients treated with
neoadjuvant therapy. Of the several grading systems compared, the RCB classification makes the best distinction between the
outcomes of the different classes, therefore we recommend the inclusion of RCB into the histopathological findings.
Keywords Breast cancer . Neoadjuvant therapy . Regression pattern . Grading systems . Residual cancer burden
Introduction
Treatment of locally advanced breast cancer (LABC) patients
has been one of the great challenges of breast oncology for a
long time. Patients with such advanced disease benefit from
treatment devised by a multidisciplinary team of specialists:
oncologists, surgeons, pathologists and radiologists [1].
Neoadjuvant therapy (NAT) has changed the management
of LABC, since it can achieve reduction or even complete
regression of the primary tumor and its metastases [2, 3].
This downstaging can allow some patients who would have
had mastectomy as surgical treatment to be treated with breast
conservation [4]. While receiving NAT, patients have to be
under constant oncological and radiological follow-up [5].
The effectiveness of NAT completed with surgical and if
needed postoperative endocrine treatment seems to be equiv-
alent with adjuvant therapy on the basis of disease-free (DFS)
and overall survivals (OS) [6, 7]. Pathological complete re-
gression occurs more frequently in triple negative or HER-2
positive cancers than in ER positive ones [8, 9].
The work-up of surgical specimen after NAT requires the
undivided attention of the pathologist. The identification of
the primary tumor bed can be challenging because of its re-
semblance to fibrotic breast tissue. Insertion of metal clips into
the tumor and/or specimen mammography can simplify the
identification process. Specimen sampling requires adequate
radio-pathological correlation [10, 11]. The evaluation of
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tumor regression after NAT has to be established with full
consideration given to radiology, gross morphology and
microscopy.
The characterization of regression differs from country to
country due to lack of international consensus on definitions.
Pathological complete regression (pCR) implies no residual
tumor in the surgical specimen, but the meaning is interpreted
variously. In some European countries, pCR generally means
the absence of in situ or invasive tumor tissue in the specimen.
A significant difference in DFS between ypT0ypN0M0 and
ypTisypN0M0was demonstrated by the German and Austrian
Breast Groups [12]. The United States Department of Health
and Human Services Food and Drug Administration Center
for Drug Evaluation and Research and the American Joint
Committee on Cancer define pCR as the absence of residual
invasive cancer in the surgical specimen [13, 14].
The histology of post-NAT tumors represents a spectrum
from pCR to tumor growth and progression (Fig. 1) [15].
Regression can be reflected by the changes in tumor size,
the cellularity of the tumor bed, the presence of lymph node
metastases and of ductal carcinoma in situ (DCIS). Since all of
these factors may affect prognosis, it is essential that all are
represented in the histopathological findings [16]. One of the
most essential prognostic factors in breast cancer after NAT
continues to be the size of the invasive cancer. In case of
unifocal tumors the largest tumor dimension will produce
the ypT category, while in cases of multifocal ones the largest
diameter of cancer cell containing tissue will be the defining
factor.
The evaluation of regression remains a complicated and
versatile task especially due to worldwide application of nu-
merous grading systems. The firstly described National
Surgical Adjuvant Breast and Bowel Project (NSABP) B18
classifies all NAT cases into two groups. The first group con-
tains pCR cases (including ypT0 and ypTis) whereas the sec-
ond group refers to all residual invasive tumor cases [17].
Further regression grading systems, namely Chevallier,
Sataloff, Miller-Payne, Denkert-Sinn, Residual Cancer
Burden (RCB), TR/NR (suggested system in the European
guidelines for measuring tumor regression and nodal regres-
sion) and Residual disease in breast and nodes (RDBN) define
the presence or absence of complete pathological regression
with one or more categories for tumors with some regression
[18–24]. The TR/NR, Sataloff and RCB systems take residual
tumor burden into account, the Chevallier grade considers the
presence of some regression, while the Denkert-Sinn grade
includes tumor size, and the Miller-Payne system integrates
change of cellularity between the biopsy and the resection
specimen. The Sataloff, TR/NR and RCB grading systems
include lymph node status as well [22, 19, 11]. The RDBN
score can be calculated by the following equation RDBN =
0,2xtumor size (mm) + Nottingham histologic grade (1–3) +
lymph node involvement (0–3). According to the RDBN
score a good (⩽3.4), a moderate (3.4 < and ⩽5.4), and poor
(>5.4) prognostic group were identified [24]. The quantifica-
tion of residual tumor can be performed by using the RCB
calculation. The algorithm was developed by Symmans and
coworkers and takes notice of the two largest diameters of the
residual tumor, the presence and proportion of DCIS and the
number of metastatic lymph nodes with the size of the largest
nodal metastasis [22]. The evaluation of RCB is supported by
the online available RCB calculator (http://www3.
mdanderson.org/app/medcalc/index.cfm?pagename=
jsconvert3).
Table 1 represents tumor regression grading systems eval-
uated in our study and defines the differences among them.
Although these grading systems are validated, none of them
are accepted internationally. The Hungarian protocol in re-
gression grading was recommended by the 3rd Hungarian
Consensus Conference on Breast Cancer in 2016 and is prac-
tically identical with the recommendation of the European
Working Group for Breast Screening Pathology (EWGBSP)
[11, 23]. In Germany, the Denkert-Sinn grade is utilized,
while in the USA and many other countries the RCB becomes
increasingly adopted.
Fig. 1 Spectrum of tumor regression: Complete pathological regression
(a), partial regression (b) and lack of regression (c) (HE, A: 4x, B and C:
10x)
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The aim of our study was to evaluate the prognostic impact
(on disease-free and overall survival) of the different tumor
regression grading systems in breast cancer patients treated
with NAT. We also aimed to identify which of the grading
systems could best reflect prognosis.
Materials and Methods
NAT receiving, consecutive patients operated on for histolog-
ically verified invasive breast carcinoma at the Department of
Surgery, University of Szeged or Bács-Kiskun County
Teaching Hospital, Kecskemét between 1999 and 2019 were
included in our retrospective study. Follow up data were col-
lected from medical charts.
The following clinical and pathological variables were ob-
tained for analysis: age, gender, localization, type of neoadju-
vant and surgical treatments, DFS and OS; histological type
and grade of cancer in previous core biopsy and surgical spec-
imen, completeness of the resection, vascular invasion, size -
possibly in 2 dimensions, ypT, ypN, ystage, tumor cell densi-
ty, tumor cellularity in biopsy and resection specimens, pres-
ence and proportion of DCIS, presence of metastasis and/or
regression in lymph nodes, size of metastatic deposits and
receptor status (estrogen receptor - ER, progesterone receptor
– PR, and human epidermal growth factor receptor-2 –
HER2). Tumor cell density was defined as the proportion of
viable tumor cells in the complete tumor bed, not including
necrosis or DCIS.
Regression grades (NSABP-B18, TR/NR, Chevallier,
Sataloff, Denkert-Sinn, Miller-Payne, and RCB) and morpho-
logical variables were correlated with DFS and OS data using
Kaplan-Meier estimates. Patients were followed from the date
of initiation of NAT until the time of recurrence or tumor-
related death. Patients alive without recurrence and patients
dying from other causes were censored at the time of the last
follow-up and death, respectively. The log-rank test was used
for pairwise comparisons. All statistical tests were two-sided
and p < 0.05 values were considered statistically significant.
The parameters found significant in the univariable models
were entered in multivariable Cox proportional hazard model
to identify factors of independent prognostic significance.
Statistical models were fitted using SPSS Statistics V.22.0
software (IBM, SSPS 22.0, Armonk, NY USA).
This retrospective study was approved by the regional eth-
ical committee of the Albert Szent-Györgyi Clinical Centre of
the University of Szeged.
Results
Data of 746 patients who underwent NAT and surgical resec-
tion were collected. The median patient age was 55 years
(range: 26–91) and 2 of themwere males. Table 2 summarizes
the oncological and surgical treatments of all patients in the
examined population. The majority of patients received pri-
mary chemotherapies, whereas 16.4% got primary endocrine
therapy. Regarding primary systemic chemotherapy, the ma-
jority of patients were given third generation (taxane contain-
ing) regimens. 11.2% of the patients had been given second
generation (anthracycline based) chemotherapeutics. Patients
who received a combination of platinum compounds with
cyclophospamide fell into the “others” category. Anti-Her2
treatment was essentially given in combination with chemo-
therapy. Concerning primary endocrine therapy, the most fre-
quent agents used were aromatase inhibitors and the average
hormonal therapy treatment period was 1 year. The majority
of patients underwent mastectomy. Re-excisions were rarely
performed and were done because of positive or close resec-
tion margins. Regional lymph nodes were examined in almost
all cases, most commonly by means of axillary lymph node
dissection.
As Table 3 demonstrates, with histological examination,
87.8% of patients had invasive carcinoma „No Special
Type” in surgical specimens. Invasive tubular, mucinous,
medullary and metaplastic breast cancers were categorized
into the others category. The presence of residual DCIS was
described in 212 cases. One fifth of the patients achieved pCR.
The most frequent pathological tumor category was ypT2
Table 2 Types of NAT and surgical treatment in the examined
population (LHRH: Luteinizing hormone-releasing hormone, HER2:
Human epidermal growth factor receptor 2, SNB: Sentinel node biopsy,
ALND: Axillary lymph node dissection)
Neoadjuvant therapy
Primary hormonal therapy (n = 123 = 100%) n %
Tamoxifen 4 3.25
Aromatase inhibitor 102 82.93
Tamoxifen and LHRH-analogue 3 2.44
Aromatase inhibitor and LHRH-analogue 14 11.38
Primary chemo- and target therapy (n = 623 = 100%) n %
Second generation chemotherapy 70 11.24
Third generation chemotherapy 550 88.28
Others 3 0.48
Anti-HER2 (in combination therapy) 91 14.60
Number of cycles should go under Primary chemo-and
target therapy)
5.60 6.00
Surgical treatment (n = 746 = 100%) n %
Breast conserving excision 249 33.38
Mastectomy 497 66.62
Re-excision 17 2.28
SNB 72 9,65
ALND 593 79,49
SNB+ALND 60 8.04
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(20.2%), while 38.9% of the patients fell in with ypN0 cate-
gory. Most cases expressed ER and PR, while HER-2 positiv-
ity was observed in 126 cases (17%). Median patient follow
up was 53.8 months (range: 4–238 months; average:
65.1 months). Relapse occured in 34.85% of cases during
the follow-up period and tumor specific death was observed
in 122 (16,3%) cases.
According to the original histopathology reports, the num-
bers of patients evaluated with the different regression grading
systems are as follows: NSABP-18 grade: 746, Chevallier-
grade: 717, Sataloff (T) grade: 494, Miller-Payne grade:
386, TR grade: 392, Denkert-Sinn grade: 348, RDBN grade:
405 and RCB: 212. Figure 2 and Supplementary Fig. 1-8
show the disease-free survival and overall survival estimates
of the different grading systems, respectively. The DFS and
OS estimates of complete pathological regression (ypT0) and
residual in situ carcinoma (ypTis) together were significantly
different from the survivals of tumors without regression and
moderate regression categories in all grading systems
(p < 0.001). There was no significant DFS and OS difference
observed between the ypT0 and ypTis categories. Survival
values associated with different partial or no response catego-
ries showed no significant differences between each other,
with the exceptions of DFS for the RCB-I vs III and II vs III
categories.
As all regression grading systems showed a significant effect
on survival in the univariable models, they were all entered in the
multivariable Cox-regression analysis. According to our results
the RCB (p = 0.019) proved to be an independent prognostic
marker for DFS, whereas the ystage (p= 0.011) and lymph node
status (p= 0.045) showed similar results for OS.
Discussion
Due to the increasing use of NAT in patients having locally
advanced breast cancer, more and more articles about its ef-
fectiveness have been published [8]. Although imaging tech-
niques serve as great options to monitor regression after NAT,
histopathological review remains the gold standard in the
evaluation procedure [25]. Although several national guide-
lines aiming at the standardization of specimen cut up and
reporting have been introduced, for example in Australia,
Belgium, Germany, the UK, Netherlands, the USA and
Hungary, there is no international agreement in the interpreta-
tion of tumor regression, in the definition of pCR, and in the
measurement of tumor size in cases where fibrosis develops as
a result of NAT or multifocality is present [11, 26–31].
Several regression grading systems have been introduced
which are based on prognostic markers such as tumor size (in
one or more dimensions), change in cellularity, presence of
DCIS, presence of regression or metastasis in lymph nodes and
the size of lymph nodemetastasis [17–23]. The definition of pCR
and the complete lack of regression -as the extreme ends of the
regression spectrum- are common features of these systems
which also define one or more subgroups for partial regression
Table 3 Morphological features of breast cancer in the examined
population (NST: Invasive carcinoma „No Special Type”, ILC:
Invasive lobular carcinoma, DCIS: Ductal carcinoma in situ, R:
Resection, V: (Lympho) vascular invasion, Pn: Perineural invasion,
HR: Hormone (estrogen and/or progesterone) receptor, HER2: Human
epidermal growth factor receptor 2; ypT and ypN categories are defined
byAJCC.Not all evaluated features were available for all cases, hence the
differences in the sums of some rows
Histological subtype (core) n %
NST 655 87.80
ILC 55 7.37
others 36 4.83
grade n %
1 35 4.69
2 246 32.98
3 420 56.30
No data 45 6.03
DCIS (present) 212 28.41
R (R1/R0) 130/616 17.42
V (V1/V0) 151/560 21.23
Pn (Pn1/Pn0) 10/324 2.99
Hormonal state n %
HR +, HER-2 - 439 58.85
HER-2 +, HR +/- 126 16.89
Triple negative 181 24.26
ypT n %
ypT0 106 14.21
ypTis 28 3.75
ypT1a 48 6.43
ypT1b 25 3.35
ypT1c 110 14.75
ypT2 151 20.24
ypT3 55 7.37
ypT4 29 3.90
No data 194 26.00
ypN n %
ypN0 290 38.87
ypN1 227 30.43
ypN2 127 17.02
ypN3 61 8.18
No data 41 5.50
ystage n %
0 9 1.21
I 75 10.05
II 209 28.02
III 207 27.75
IV 6 0.80
No data 240 32.17
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categories. Despite of the relative abundance of regression grad-
ing systems, there is a lack of international consensus on their
application. All grading systems attempt to quantify the degree of
regression or the amount of residual tumor, and there is agree-
ment that a quantitative characterization of tumor regression is
necessary for the evaluation of the effectiveness of NAT, and
may have further role in therapeutic decisions (e.g. alternative
treatments if no regression is present).
Although the presence of residual DCIS has been reported to
convey a worse prognosis than complete absence of in situ and
invasive carcinoma, there was no significant difference between
OS andDFS estimates of ypT0ypN0 and ypTisypN0.Our results
are therefore supporting the more permissive definition of pCR
(including ypTis) defined by the United States’ FDA and en-
dorsed by the AJCC [13, 14] and the European Guidelines
[23]. Our findings regarding the prognostic impact of pCR are
in keeping with those of others, since patients with pCR had a
favorable prognosis (both in DFS and OS) compared to patients
having partial regression. Concerning the subcategories of partial
regression, we observed significant differences only between
DFS estimates of certain RCB classes, namely between RCB-I
vs. RCB-III and RCB-II vs. RCB-III classes. No other regression
classification system showed subgroups of partial response with
significant differences between each other.
The RCB systemwas developed by Symmans and coworkers
in 2007. In their study, the prognostic role of morphological
variables was evaluated by Cox-regression, and from variables
found statistically significant, a complex equation was produced
to determine the RCB index score. The RCB index score was
correlated with survival data and cut-off scores were assigned to
identify the RCB classes. In concordance with the original results
by Symmans et al., there were no significant differences in DFS
and OS estimates between RCB-0 (pCR) and RCB-I (nearly
pCR) classes. Furthermore, the multivariable Cox regression
models for DFS suggest that the RCB system is the only signif-
icant prognosticator among regression grades (p = 0.019) [22].
In a subsequent publication, Symmans and co-authors have
demonstrated that the RCB is a prognostic marker indepen-
dent from the type of primary chemotherapeutic regime and
significant differences have been described between RCB
classes among hormone receptor positive (ER+ and/or PR+,
HER2-), HER-2 positive (hormone receptor positive or nega-
tive) and triple negative (ER-, PR, HER2-) breast cancer cases
[32]. Our results support these conclusions, and moreover, by
adding primary endocrine therapy to our calculations, RCB
remained an independent prognostic marker.
Considering literature data and our results, RCB is highly
recommended to be included in routine histopathological re-
ports of breast cancers treated with NAT. Although most ele-
ments of RCB are routinely part of histopathological reports,
the characterization of some others, namely the second largest
dimension of tumor size, the cellularity and the proportion of
DCIS, require experience in practice. The standardization of
reporting these markers are supported by the concise guidance
at the RCB calculator website [32].
Corben and co-authors emphasized the role of the presence
and size of lymph node metastasis. Those grading systems that
include lymph node status (RCB, Sataloff, TR-NR, RDBN)
Fig. 2 Kaplan-Meier evaluation of the RCB grading system for DFS and
OS. Significant differences were found between DFS estimates of pCR
vs. RCB-II (p < 0.001), pCR vs. RCB-III (p < 0.001), RCB-I vs. RCB-III
(p = 0.035), RCB-II vs. RCB-III (p = 0.05). Regarding OS, significant
differences were observed between estimates of pCR vs. RCB-II (p =
0.005) and pCR vs. RCB-III (p < 0.001), respectively (RCB: Residual
Cancer Burden, DFS: disease-free survival, OS: overall survival, pCR:
pathological complete regression)
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show better correlationwith long term survival than those includ-
ing only invasive tumor size and cellularity [5]. In keeping with
Corben’s results, we found the ypN category as a significant
prognostic marker according to OS estimates. The presence of
nodal metastasis was associated with poor prognosis regardless
of the presence or absence of nodal regression. Corben and co-
workers suggested the RDBN grade to be the most optimal re-
gression grading system among the 5 investigated [5]. However,
we found no significant differences in DFS or OS between the
RDBN groups with Cox regression. This contrast may be due to
different factors, like the differences in patients and in cohort
sizes (62 vs 746) and the inclusion of primary endocrine therapy
in the present analysis.
Concerning the limitations of our study, it has to be men-
tioned that not all grading systems were assessed in all cases.
Several patients had gone through lymphadenectomy prior to
NAT and this could influence the prognostic value of a given
grading system. Furthermore, the institution where the core nee-
dle biopsy was taken differed from the place of surgery in many
cases, therefore the comparison of these samples was not always
possible. On the other hand, the strengths of our evaluation
include a large cohort of patients having primary endocrine
treatment or chemotherapy with relatively long follow-up data.
Ourmulticenter studywas based on twoHungarian departments
with identical cut-up and reporting protocol, following the rec-
ommendations of the 3rd Hungarian Consensus Conference on
Breast Cancer. Although not all grading systemswere evaluated
in all cases, even the smallest group included more than 200
patients, and this proved sufficient for statistical analysis.
In our retrospective study involving the grading of re-
sponse to NAT in 746 patients, we have evaluated and com-
pared the impact of different regression grading systems on
DFS and OS. According to our results, the RCB was the best
prognostic factor, therefore we would encourage its utilization
in routine histopathological reports.
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